Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ATBPFOTCMKTS:HSTCNASDAQ:NBRVNASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATBPFAntibe Therapeutics$0.22$0.22$0.11▼$0.89$11.42M0.5127,352 shsN/AHSTCHST Global$0.83+10.7%$0.73$0.23▼$1.11$47.95M-1.191,185 shs101 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs93 shsSKYESkye Bioscience$1.82+1.7%$1.54$1.14▼$13.51$56.37M1.88349,652 shs415,800 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATBPFAntibe Therapeutics0.00%0.00%0.00%0.00%0.00%HSTCHST Global0.00%+40.85%-9.64%-9.64%+15.38%NBRVNabriva Therapeutics0.00%0.00%0.00%+4,900.00%+4,900.00%SKYESkye Bioscience+4.07%+24.74%-24.15%-35.70%-86.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATBPFAntibe TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASKYESkye Bioscience1.076 of 5 stars3.50.00.00.02.70.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATBPFAntibe Therapeutics 0.00N/AN/AN/AHSTCHST Global 0.00N/AN/AN/ANBRVNabriva Therapeutics 0.00N/AN/AN/ASKYESkye Bioscience 3.00Buy$16.60812.09% UpsideCurrent Analyst Ratings BreakdownLatest ATBPF, NBRV, SKYE, and HSTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.003/21/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATBPFAntibe TherapeuticsN/AN/AN/AN/A$0.58 per shareN/AHSTCHST GlobalN/AN/AN/AN/AN/AN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00SKYESkye BioscienceN/AN/AN/AN/A($0.17) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATBPFAntibe Therapeutics-$14.73M-$0.25N/A∞N/AN/A-56.48%-29.07%N/AHSTCHST Global-$150K-$0.02N/A∞N/AN/A-13,072.91%-31.66%N/ANBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ASKYESkye Bioscience-$37.65M-$0.72N/AN/AN/AN/A-45.78%-37.44%N/ALatest ATBPF, NBRV, SKYE, and HSTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024SKYESkye Bioscience-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATBPFAntibe TherapeuticsN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATBPFAntibe TherapeuticsN/A10.0610.06HSTCHST GlobalN/A0.250.25NBRVNabriva Therapeutics0.120.850.52SKYESkye BioscienceN/A14.1914.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATBPFAntibe TherapeuticsN/AHSTCHST GlobalN/ANBRVNabriva Therapeutics0.27%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipATBPFAntibe Therapeutics9.00%HSTCHST Global65.82%NBRVNabriva Therapeutics1.63%SKYESkye Bioscience3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATBPFAntibe Therapeutics1152.98 million48.24 millionNot OptionableHSTCHST Global157.77 million16.33 millionNot OptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableSKYESkye Bioscience1130.98 million29.43 millionOptionableATBPF, NBRV, SKYE, and HSTC HeadlinesRecent News About These CompaniesSkye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive PlanApril 25 at 8:33 PM | quiverquant.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 25 at 8:06 PM | globenewswire.comWilliam Blair Comments on Skye Bioscience Q1 EarningsApril 19, 2025 | americanbankingnews.comAnalysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) Price Target at $16.60April 19, 2025 | americanbankingnews.comRx Rundown: Merck, the CDC, GSK and moreApril 18, 2025 | mmm-online.comWilliam Blair Predicts Skye Bioscience Q2 EarningsApril 18, 2025 | marketbeat.comAnalysts Offer Predictions for Skye Bioscience Q2 EarningsApril 18, 2025 | americanbankingnews.comA Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash ValueApril 16, 2025 | seekingalpha.comSkye Bioscience announces new preclinical data for nimacimabApril 15, 2025 | markets.businessinsider.comSkye Bioscience Stock Rises on Preclinical Data for Weight Loss DrugApril 15, 2025 | marketwatch.comSkye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal ModelsApril 15, 2025 | benzinga.comSkye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical ModelApril 15, 2025 | globenewswire.comSkye Bioscience to Conduct Meetings at Piper Sandler ConferenceApril 14, 2025 | globenewswire.comWhy Skye Bioscience, Inc.’s (SKYE) Stock Is Down 12.88%April 1, 2025 | aaii.comSkye Bioscience promotes Tu Diep to COO postMarch 25, 2025 | thepharmaletter.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by BrokeragesMarch 25, 2025 | marketbeat.comEarnings call transcript: Skye Bioscience Q4 2024 highlights financials, product progressMarch 22, 2025 | uk.investing.comSkye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | insidermonkey.comSkye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 22, 2025 | finanznachrichten.deSkye Bioscience price target lowered to $14 from $18 at Craig-HallumMarch 22, 2025 | markets.businessinsider.comSkye Bioscience’s Positive Earnings Call Highlights Nimacimab ProgressMarch 21, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATBPF, NBRV, SKYE, and HSTC Company DescriptionsAntibe Therapeutics OTCMKTS:ATBPF$0.22 0.00 (0.00%) As of 04/16/2025Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.HST Global OTCMKTS:HSTC$0.83 +0.08 (+10.67%) As of 11:30 AM EasternHST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Skye Bioscience NASDAQ:SKYE$1.82 +0.03 (+1.68%) Closing price 04:00 PM EasternExtended Trading$1.76 -0.06 (-3.24%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
